{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:50:24Z","timestamp":1782903024440,"version":"3.54.5"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":3203,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[1996,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Deprenyl and Tocopherol Antioxidant Therapy of Parkinsonism (DATATOP) trial was designed to test outcomes from treatment with 10 mg of deprenyl and\/or 2,000 mg of tocopherollday in 800 untreated patients with Parkinson's disease. The need of subjects for symptomatic treatment with levodopa and the conversion of all subjects to open\u2010label deprenyl made it possible to study the long\u2010term effect of early deprenyl and tocopherol treatment on the later development of levodopa\u2010associated side effects. The rate of developing these side effects did not differ among the original treatment groups (early versus late deprenyl and tocopherol versus nontocopherol). About 50% of subjects developed \u201cwearing off,\u201d 30% dyskinesias, and 25% \u201cfreezing\u201d in each group. At the end of the study, the groups were similarly disabled on the Hoehn\u2010Yahr, Schwab\u2010England, and Unified Parkinsonapos;s Disease Rating scales and took similar amounts of levodopa. Young subjects were more likely to develop wearing off, women to develop dyskinesias, and older subjects with rapidly progressive disease to develop freezing. We conclude that prior treatment with deprenyl or tocopherol did not reduce the occurrence of subsequent levodopa\u2010associated adverse effects in this population.<\/jats:p>","DOI":"10.1002\/ana.410390107","type":"journal-article","created":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T16:31:43Z","timestamp":1104597103000},"page":"37-45","source":"Crossref","is-referenced-by-count":260,"title":["Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa"],"prefix":"10.1002","volume":"39","author":[{"name":"Parkinson Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196902132800701"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-83-4-456"},{"key":"e_1_2_1_4_2","first-page":"283","article-title":"The impact of treatment with levodopa on Parkinson's disease","volume":"195","author":"Shaw KM","year":"1980","journal-title":"Q J Med"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1985.tb03173.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)91416-1"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.24.5.431"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.29.9_Part_1.1253"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1518"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220105"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.9.1410"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.5.622"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.3.380"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1983.tb01522.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212004"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410260518"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1989.tb14919.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(87)90117-8"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520460028009"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390106"},{"key":"e_1_2_1_21_2","first-page":"205","volume-title":"Statistical methods in medical research","author":"Armitage P","year":"1987"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1976.220"},{"key":"e_1_2_1_23_2","volume-title":"Monographs on statistics and applied probability","author":"Cox DR","year":"1984"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301213280305"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1986.tb01747.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90181-G"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1523\/JNEUROSCI.13-09-04042.1993","article-title":"Rescue of axotonized immature rat facial motoneurons by K(\u2010)\u2010deprenyl: stereospecificity and independence from monoamine oxidase inhibition","volume":"13","author":"Ansari KS","year":"1993","journal-title":"J Neurosci"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(85)90010-4"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.9.1337"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320614"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.2.217"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410340423"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02251203"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0149-7634(86)90029-1"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410240303"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410240304"},{"key":"e_1_2_1_38_2","first-page":"497","volume-title":"Parkinsoxi\u2010specific motor and mental disorders, role of the pallidum: pathophysiological, biochemical and therapeutic aspects. Advances in neurology","author":"Narabayashi H","year":"1984"},{"key":"e_1_2_1_39_2","first-page":"593","volume-title":"Parkinson's disease","author":"Narabayashi H","year":"1986"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.410390107","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.410390107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T18:27:40Z","timestamp":1698344860000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.410390107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1996,1]]}},"alternative-id":["10.1002\/ana.410390107"],"URL":"https:\/\/doi.org\/10.1002\/ana.410390107","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,1]]}}}